- Study evaluated 115 AML transplant recipients; 74 had full serial NGS data.
- Post-transplant mutations were found in 35 patients, and 31 relapsed.
- TET2 and DNMT3A mutations had the strongest relapse associations (OR 3.35 and 1.97).
- Detectable mutations after transplant raised relapse risk more than fourfold (HR 4.34).
- High donor chimerism correlated with remission, even when low-level variants remained.
- Persistent low-level variants may reflect CHIP, not residual leukemia.
- Integrating NGS mutation profiling with chimerism could improve relapse prediction and follow-up.
Study: Genetic Testing May Predict AML Relapse
Conexiant
November 14, 2025
